Insights
Insights From Our Experts
Articles
Transitioning an Enterprise Literature Monitoring Program with EVERSANA ORCHESTRATE™ PV
How one enterprise client restored transparency and compliance in global literature monitoring Enterprise pharmacovigilance teams often face the challenge of managing high-volume literature surveillance while maintaining regulatory compliance and audit readiness. This case study highlights how…
Consolidating Data Strategy For Global Success
Data strategy isn’t just an operational detail, it’s the foundation of a successful global launch. Companies that neglect early planning risk costly missteps, from compliance gaps to duplicated investments. We believe data strategy is launch strategy. It’s what ensures evidence generation, regulatory…
Predicting PICOs for EU HTA: The Validated PICO Planner Approach Based on Retrospective Analysis
The EU Health Technology Assessment Regulation (EU HTAR) and Joint Clinical Assessment (JCA) aim to harmonize clinical evaluations across Europe while preserving national HTA decisions. To navigate this complexity, early and strategic PICO (Population, Intervention, Comparator,…
New Direct-to-Employer Access Model Provides Options for Employers to Improve Access to Weight Loss Medications
Waltz Health, an EVERSANA company, has introduced a new Direct-to-Employer (DTE) Access Model for FDA-approved obesity management medicines. The model, developed in collaboration with leading drug manufactures including Eli Lilly and Novo Nordisk, gives employers a new,…
Pharmatizing AI: How Artificial Intelligence Is Transforming Pharma
From discovery to delivery, artificial intelligence is reshaping how pharma works—and the change is accelerating. As Global Co-Host and Presenting Sponsor of Frontiers Health 2025, our team led a critical conversation on AI in pharma. With Roberto Ascione, President…
The Oncologist’s Next Ally: Why Cancer Is Forging the Future of Clinical AI
Step into the future of medicine, where the battle against cancer is redefining what artificial intelligence (AI) can achieve in clinical care. In The Oncologist’s Next Ally: Why Cancer Is Forging the Future of Clinical AI,…
Driving Measurable Impact for Pharma Brands: How Our AI Agency Platform Improves Operational Models
Our AI Agency platform is redefining how life sciences brands approach omnichannel marketing, campaign development and so much more with unmatched speed and precision. Recently our Chief Innovation Officer, Faruk Capan, spoke with PharmaVoice about the platform and how it’s built to…
Brave New Commercialisation World
The pharma commercialization landscape is evolving at an unprecedented speed. At Frontiers Health 2025, our team joined industry leaders to discuss how global launches, pricing strategies and patient access are being reshaped by policy changes and…
Google Cloud Spotlights EVERSANA: A Milestone for Pharma Innovation
When one of the world’s leading technology companies tells your story, it’s more than recognition. It’s validation of a vision that’s reshaping an entire industry. Google Cloud recently published a feature on EVERSANA’s approach to transforming…
EVDAS 2026: From Regulatory Requirement to Signal Advantage
The European Medicines Agency (EMA) has adopted Implementing Regulation (EU) 2025/1466, amending Regulation 520/2012 and reinforcing the requirement for ongoing monitoring of EudraVigilance data. From 12 February 2026, Marketing Authorisation Holders (MAHs) in the EU/EEA must…